Darifenacin

CLINICAL USE

Symptomatic treatment of urinary incontinence, frequency or urgency

DOSE IN NORMAL RENAL FUNCTION

7.5–15 mg once daily

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :426.6 (507.5 as hydrobromide)

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :98

%Excreted unchanged in urine &nbsp &nbsp : 3

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :163 litres

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :13–19/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : Dose as in normal renal function

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux &nbsp :Unlikely to be dialysed. Dose as in normal renal function

CAV/VVHD &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsAntifungals: concentration increased by ketoconazole – avoid concomitant useAntivirals: avoid concomitant use with amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavirCalcium-channel blockers: avoid concomitant use with verapamilCiclosporin: avoid concomitant use

Tags: post-by-auto-php